

# Susana M Campos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10016401/publications.pdf>

Version: 2024-02-01

27  
papers

1,312  
citations

567144

15  
h-index

580701

25  
g-index

27  
all docs

27  
docs citations

27  
times ranked

1443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms. <i>American Journal of Surgical Pathology</i> , 2022, 46, 169-178.	2.1	12
2	A phase I study of AZD2171 and Temezirolimus in patients with advanced gynecological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 423-430.	1.1	1
3	Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1531-1539.	0.8	88
4	Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2021, 161, 581-586.	0.6	5
5	Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain. <i>Oncologist</i> , 2021, 26, e2102-e2109.	1.9	0
6	Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. <i>Gynecologic Oncology</i> , 2020, 159, 72-78.	0.6	41
7	Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 154, 95-101.	0.6	29
8	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 153, 471-478.	0.6	18
9	Surveillance Imaging in Patients With Endometrial Cancer in First Remission. <i>Current Problems in Diagnostic Radiology</i> , 2018, 47, 311-316.	0.6	3
10	Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. <i>Cancer</i> , 2016, 122, 3297-3306.	2.0	2
11	Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1154-1164.e12.	1.5	88
12	Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 497-504.	2.0	156
13	Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 54-57.	0.6	2
14	A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 215-220.	0.6	46
15	Young Women Diagnosed with Early-Stage Ovarian Cancer or Borderline Malignancy of the Ovary: A Focus on Fertility and Sexual Function. <i>Journal of Psychosocial Oncology</i> , 2012, 30, 387-401.	0.6	10
16	Antimitotic Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 607-628.	0.9	14
17	Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2010, 15, 390-398.	1.0	6
18	A Current Review of Targeted Therapeutics for Ovarian Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-11.	0.6	45

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Malignant Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 154-159.	0.8	96
20	Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5601-5606.	0.8	285
21	Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. <i>Cancer Investigation</i> , 2008, 26, 757-768.	0.6	9
22	Role of pegylated liposomal doxorubicin in ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 96, 10-18.	0.6	99
23	Evolving treatment approaches for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, S1-S7.	1.1	3
24	Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5597-5604.	0.8	115
25	Aromatase Inhibitors for Breast Cancer in Postmenopausal Women. <i>Oncologist</i> , 2004, 9, 126-136.	1.9	90
26	Hormonal Therapy in Postmenopausal Women with Breast Cancer. <i>Oncology</i> , 2003, 64, 289-299.	0.9	22
27	The impact of anemia and its treatment on patients with gynecologic malignancies. <i>Seminars in Oncology</i> , 2002, 29, 7-12.	0.8	27